⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of EpiDisease and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
EpiDisease
↗Valencia, Spain
EpiDisease is a biotechnology company specializing in the development and commercialization of proprietary in vitro diagnostic (IVD) products based on epigenetic biomarkers. Founded as a spin-off from the Centre for Biomedical Network Research (CIBER-ISCIII) and the University of Valencia, the company leverages expertise in DNA methylation, histone modifications, and miRNA analysis to provide precision diagnostic and prognostic tools for complex human diseases.
The company's core focus areas include Adolescent Idiopathic Scoliosis (AIS), sepsis, and aging. EpiDisease integrates genetics, epigenetics, and AI-driven software to improve clinical decision-making and patient outcomes. They are recognized for their innovative approach to personalized medicine and maintain active research collaborations within the European Union's innovation ecosystem.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2014
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$1.0M
Investors:Arquimea, Fundación Botín (Mind the Gap program)
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (ScoliGEN)
Modalities:Epigenetics, Genetics, AI/Digital Health
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Matisse Pharmaceuticals (joint program for sepsis diagnosis and therapy), DiBaN consortium (EU-funded project for metabolic health)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
José Luis García Giménez - CEO / Founding Partner
James Webb - Chief Commercial Officer
Scientific Founders:José Luis García Giménez, Salvador Mena Mollá, Lorena Peiró Chova
LINKS
Website:epidisease.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with EpiDisease. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.